All lobbying filings

Mehlman Consulting, Inc.

Mehlman Consulting, Inc. filed a Q3 report for Ultragenyx Pharmaceutical, Inc. on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Ultragenyx Pharmaceutical, Inc. · Biopharmaceutical Company

As filed: MEHLMAN CONSULTING, INC. for ULTRAGENYX PHARMACEUTICAL, INC.

All filings by Mehlman Consulting, Inc. · Everything Ultragenyx Pharmaceutical, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 1

SEAN BRADY New on this filing

Previously held: Dir Leg Affairs (DOC, Intl Trade Admin); CoS, Dep. CoS/ LD, SLA, LA, Staff Asst (Rep. Vern Buchanan); Intern (Rep. Fred Upton); Intern (Rep. Dan Lungren)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues relating to rare disease and patient access. Issues related to newborn screening.

Budget/Appropriations

FY27 Appropriations (H.R.8646, Agriculture, Rural Development, Food and Drug Administration)

Bills named in this filing 1

H.R. 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.